OPTN/SRTR 2019 annual data report: liver.
Am J Transplant. 2021; 21: 208-315
Transplanting hepatitis C–positive kidneys.
N Engl J Med. 2015; 373: 303-305
Association between ethnicity and kidney transplant waitlist outcomes beyond estimated post-transplant survival score.
Transpl Int. 2021; 34: 1837-1844https://doi.org/10.1111/tri.13965
Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement.
J Heart Lung Transplant. 2020; 39: 418-432
Hepatitis C viraemic organs in solid organ transplantation.
J Hepatol. 2021; 74: 716-733
Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors.
Hepatology. 2019; 69: 2381-2395https://doi.org/10.1002/hep.30540
Victory and defeat at Heraclea – treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.
J Hepatol. 2014; 60: 6-8
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
J Hepatol. 2014; 60: 78-86
Changes in utilization and discard of hepatitis C-infected donor livers in the recent era.
Am J Transpl. 2017; 17: 519-527
Meta-analysis of observational studies: hepatitis C and survival after renal transplant.
J Viral Hepat. 2014; 21: 314-324
The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study.
Ann Intern Med. 2018; 168: 702-711
Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
Am J Transpl. 2019; 19: 1380-1387
The rise of the opioid epidemic and hepatitis C–positive organs: a new era in liver transplantation.
Hepatology. 2018; 67: 1600-1608https://doi.org/10.1002/hep.29572
Liver transplantation of HCV-viremic donors into HCV-negative recipients in the United States: increasing frequency with profound geographic variation.
Transplantation. 2021; 105: 1285-1290
Donor characteristics and regional differences in the utilization of HCV-positive donors in liver transplantation.
JAMA Netw Open. 2020; 3: e2027551
Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation.
Liver Transplant. 2004; 10: 1263-1268
Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience.
Transpl Infect Dis. 2021; 23: e13540
Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard.
Transpl Infect Dis. 2020; 22: e13204
Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: histological and virologic outcome.
Clin Transplant. 2021; 35: e14281
Biopsy specimens from allograft liver contain histologic features of hepatitis C virus infection after virus eradication.
Clin Gastroenterol Hepatol. 2017; 15: 1279-1285
Use of hepatitis C nucleic acid test–positive liver allografts in hepatitis C virus seronegative recipients.
Liver Transplant. 2020; 26: 673-680
Hepatitis C and kidney disease: a narrative review.
J Adv Res. 2017; 8: 113-130
Letter to the editor: safety first: favoring prophylactic/preemptive over delayed treatment in D+/R- transplants.
Hepatology. 2020; 72: 787
Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays.
Asian J Transfus Sci. 2014; 8: 19-25
Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature.
J Viral Hepat. 2001; 8: 87-95
Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment.
Clin Infect Dis. 2006; 43: 1277-1283
Immune suppression leading to hepatitis C virus re-emergence after sustained virological response.
J Med Virol. 2008; 80: 1720-1722
Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.
Lancet Oncol. 2002; 3: 333-340
Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.
Hepatology. 2018; 67: 1673-1682
Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients.
J Am Coll Surg. 2019; 228: 560-567
Treat chronic hepatitis C virus infection in decompensated cirrhosis – pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
J Viral Hepat. 2016; 23: 408-418
Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
J Hepatol. 2021; 74: 873-880
Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
Lancet Gastroenterol Hepatol. 2019; 4: 771-780
Liver transplantation using hepatitis C virus-viremic donors into hepatitis C virus-aviremic recipients as standard of care.
Liver Transpl. 2021; 27: 548-557
Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: a single-center study.
Clin Transplant. 2020; 34: e13761
Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation.
Clin Transplant. 2021; 35: e14386https://doi.org/10.1111/ctr.14386
Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience.
Hepatology. 2020; 72: 32-41
Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A Veterans Transplant Center Report.
Transpl Infect Dis. 2021; 23: e13466https://doi.org/10.1111/tid.13466
Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis.
Ann Hepatol. 2021; 24: 100318
International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant recipients.
Transplantation. 2017; 101: 956-967
Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.
Transpl Infect Dis. 2019; 21: e13194
Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors.
Hepatology. 2021; 73: 2110-2123
12 Weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
Hepatology. 2018; 68: 1277-1287
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
Liver Transpl. 2016; 22: 1536-1543
Multicenter study to transplant hepatitis C–infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection.
J Am Soc Nephrol. 2020; 31: 2678-2687
Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study.
Ann Intern Med. 2021; 174: 137-138
Outcomes of the treatment with glecaprevir/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
Clin Transplant. 2020; 34: e13989
Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors.
Semin Thorac Cardiovasc Surg. 2021; 33: 407-415
Heart and lung transplants from HCV-infected donors to uninfected recipients.
N Engl J Med. 2019; 380: 1606-1617
Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.
Am J Transplant. 2020; 20: 739-751
Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management.
Transplantation. 2016; 100: 2661-2670
Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients.
Liver Transpl. 2007; 13: 516-522
Post–liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.
Liver Transplant. 2010; 16: 1228-1235https://doi.org/10.1002/lt.22175
Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis.
Liver Transpl. 2013; 19: 78-88
Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels.
Liver Transpl Surg. 1998; 4: 15-21
The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.
Liver Transplant. 2003; 9: S28-S34
Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation.
Hepatol Res. 2011; 41: 328-339
Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.
Hepatology. 1996; 23: 971-976
Histological and clinical outcome after liver transplantation for hepatitis C.
Hepatology. 1997; 26: 1646-1652
Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience.
Am J Transpl. 2019; 19: 3046-3057
Acute rejection increases risk of graft failure and death in recent liver transplant recipients.
Clin Gastroenterol Hepatol. 2017; 15: 584-593 e2
Acute cellular rejection after liver transplantation: variability, morbidity, and mortality.
Liver Transpl Surg. 1995; 1: 10-15
Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access.
Clin Transplant. 2020; 34: e13833
Transplantation of HCV-infected organs into uninfected recipients: advance with caution.
Am J Transpl. 2019; 19: 960-961
Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation.
Transplantation. 2017; 101: 968-973
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update.
Clin Pharm. 2019; 58: 1237-1263
Patients with renal impairment.
Recommendations for testing, managing, and treating hepatitis C.
EASL recommendations on treatment of hepatitis C: final update of the series(☆).
J Hepatol. 2020; 73: 1170-1218
Central nervous system complications in liver transplant recipients–incidence, timing, and long-term follow-up.
Clin Transplant. 2000; 14: 1-7
Seizure treatment in transplant patients.
Curr Treat Options Neurol. 2012; 14: 332-347
Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study.
Circulation. 2014; 130: 1353-1362
EASL recommendations on treatment of hepatitis C 2018.
J Hepatol. 2018; 69: 461-511
Cardiovascular risk management and hepatitis C: combining drugs.
Clin Pharm. 2019; 58: 565-592
Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.
Int J Antimicrob Agents. 2020; 55: 105934
5PSQ-029 Safe administration of sofosbuvir/velpatasvir in a patient with percutaneous endoscopic gastrostomy.
British Medical Journal Publishing Group,
Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube.
J Clin Pharm Ther. 2018; 43: 730-732
Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered via a percutaneous endoscopic gastrostomy tube.
J Pharm Pract. 2018; 31: 522-524
A phase 1 study to evaluate the effect of crushing, cutting into half, or grinding of glecaprevir/pibrentasvir tablets on exposures in healthy subjects.
J Pharm Sci. 2018; 107: 1724-1730
Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy.
Clin Gastroenterol Hepatol. 2019; 17: 739-747. e8
Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.
Am J Transplant. 2018; 18: 2457-2464
Trial of transplantation of HCV-infected kidneys into uninfected recipients.
N Engl J Med. 2017; 376: 2394-2395
Twelve-month outcomes after transplant of hepatitis C–infected kidneys into uninfected recipients: a single-group trial.
Ann Intern Med. 2018; 169: 273-281
Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Transpl Infect Dis. 2019; 21: e13146
Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus–infected donors to noninfected recipients: an open-label nonrandomized trial.
Ann Intern Med. 2018; 168: 533-540
Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study.
Transpl Int. 2019; 32: 710-716
Pan-genotype pre-exposure prophylaxis (PrEP) allows transplantation of HCV-positive donor kidneys to negative transplant recipients.
J Clin Med. 2021; 10: 89
Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: implications for therapeutic planning.
Am J Transplant. 2020; 20: 1619-1628
#Hepatitis #VirusPositive #Organs #Hepatitis #VirusNegative #Recipients